Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield
Go back to Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield| iShares Diversified Alternatives Trust (NASDAQ: ALT) | Delayed: 3.11 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.11 | 52 Week High | $54.24 | |||
| Open | $3.11 | 52 Week Low | $48.35 | |||
| Day High | $3.11 | P/E | N/A | |||
| Day Low | $3.11 | EPS | $0.00 | |||
| Volume | 14,912 | |||||
